Immunophenotyping invasive breast cancer: Paving the road for molecular imaging

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Vermeulen, Jeroen F ^a   van Brussel, Aram S A ^a   van der Groep, Petra ^a   Morsink, Folkert H M ^a   Bult, Peter ^b   van der Wall, Elsken ^a   van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody panel; Immunohistochemistry; Invasive breast cancer; Optical imaging; Tumor markers

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE TRANSPORTER 1; MEMBRANE PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MOLECULAR IMAGING; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL NOISE RATIO; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOPHENOTYPING; MAMMARY GLANDS, HUMAN; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR IMAGING; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84862180972     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-240     Document Type: Article

References (46)

1. Paap E, Broeders MJ, van Schoor G, Otten JD, Verbeek AL. Large increase in a Dutch woman's lifetime risk of developing breast cancer. Eur J Cancer 2008, 44:1485-1487. 10.1016/j.ejca.2008.04.008, 18479909.
2. Incidentie van invasive tumoren naar geslacht en lokalisatie per incidentiejaar (1989-2008) [http://www.ikcnet.nl/page.php?id=2902&nav_id=114].
3. Sterfte aan kanker naar geslacht en lokalisatie en jaar van overlijden (1989-2008) http://www.ikcnet.nl/uploaded/docs/Landelijk/cijfers/incidentie%202008/B1_NL.xls.
4. Medina-Franco H, Abarca-Perez L, Garcia-Alvarez MN, Ulloa-Gomez JL, Romero-Trejo C, Sepulveda-Mendez J. Radioguided occult lesion localization (ROLL) versus wire-guided lumpectomy for non-palpable breast lesions: a randomized prospective evaluation. J Surg Oncol 2008, 97:108-111. 10.1002/jso.20880, 18181162.
5. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002, 184:383-393. 10.1016/S0002-9610(02)01012-7, 12433599.
6. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. Am J Roentgenol 1995, 165:1373-1377.
7. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005, 293:1245-1256. 10.1001/jama.293.10.1245, 3149836, 15755947.
8. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993, 270:2444-2450. 10.1001/jama.1993.03510200050031, 8230621.
9. Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996, 312:273-276. 10.1136/bmj.312.7026.273, 2349888, 8611781.
10. Moadel RM. Breast cancer imaging devices. Semin Nucl Med 2011, 41:229-241. 10.1053/j.semnuclmed.2010.12.005, 21440698.
11. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 2007, 146:502-510.
12. Bos R, van der Hoeven JJ, van der Wall E, van der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002, 20:379-387. 10.1200/JCO.20.2.379, 11786564.
13. Oude Munnink TH, Nagengast WB, Brouwers AH, Schroder CP, Hospers GA, Lub-de Hooge MN, Van der Wall E, van Diest PJ, Vries EG. Molecular imaging of breast cancer. Breast 2009, 18(Suppl 3):S66-S73.
14. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7:626-634. 10.1016/j.cbpa.2003.08.007, 14580568.
15. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008, 26:4012-4021. 10.1200/JCO.2007.14.3065, 2654310, 18711192.
16. Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng 2006, 8:1-33. 10.1146/annurev.bioeng.8.061505.095831, 16834550.
17. Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol 2009, 16:2717-2730. 10.1245/s10434-009-0609-z, 2749177, 19609829.
18. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007, 48:1501-1510. 10.2967/jnumed.107.042234, 17785729.
19. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, Evangelista G, Montruccoli G, Bevilacqua G. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol 2004, 204:140-146. 10.1002/path.1626, 15376259.
20. Gee MS, Upadhyay R, Bergquist H, Alencar H, Reynolds F, Maricevich M, Weissleder R, Josephson L, Mahmood U. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 2008, 248:925-935. 10.1148/radiol.2482071496, 2798096, 18647846.
21. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008, 14:3840-3849. 10.1158/1078-0432.CCR-07-4076, 3398736, 18559604.
22. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581. 10.1002/cncr.11246, 12627523.
23. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93:309-314. 10.1093/jnci/93.4.309, 11181778.
24. van der Groep P, Bouter A, van der Zanden R, Menko FH, Buerger H, Verheijen RH, van der Wall E, van Diest PJ. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2004, 96:712-713. author reply 714.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
26. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006, 59:611-617. 10.1136/jcp.2005.032151, 1860390, 16603649.
27. Packeisen J, Korsching E, Herbst H, Boecker W, Buerger H. Demystified...tissue microarray technology. Mol Pathol 2003, 56:198-204. 10.1136/mp.56.4.198, 1187321, 12890740.
28. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 2002, 325:648-651.
29. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012, 25:398-404. 10.1038/modpathol.2011.174, 22056953.
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
31. Corlu A, Choe R, Durduran T, Rosen MA, Schweiger M, Arridge SR, Schnall MD, Yodh AG. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express 2007, 15:6696-6716. 10.1364/OE.15.006696, 19546980.
32. van de Ven S, Wiethoff A, Nielsen T, Brendel B, van der Voort M, Nachabe R, van der Mark M, van Beek M, Bakker L, Fels L, et al. A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients. Mol Imaging Biol 2010, 12:343-348. 10.1007/s11307-009-0269-1, 2864903, 19798535.
33. van Scheltinga AG T, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 2011, 52:1778-1785. 10.2967/jnumed.111.092833, 21990576.
34. Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol 2008, 16:121-127. 10.1097/PAI.0b013e318047df6d, 18227732.
35. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007, 127:103-113. 10.1309/TDP92PQLDE2HLEET, 17145637.
36. Carracedo A, Egervari K, Salido M, Rojo F, Corominas JM, Arumi M, Corzo C, Tusquets I, Espinet B, Rovira A, et al. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res 2009, 11:402. 10.1186/bcr2239, 2688943, 19439036.
37. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010, 119:283-293. 10.1007/s10549-009-0345-x, 19238537.
38. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17.
39. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010, 201:102-110. 10.1016/j.cancergencyto.2010.05.015, 20682394.
40. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007, 20:208-214. 10.1038/modpathol.3800731, 17192791.
41. Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, Kim J, Grobmyer SR, Carter WB, Vagner J, et al. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res 2011, 71:1050-1059. 10.1158/0008-5472.CAN-10-3091, 21169406.
42. Watson PH, Chia SK, Wykoff CC, Han C, Leek RD, Sly WS, Gatter KC, Ratcliffe P, Harris AL. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer 2003, 88:1065-1070. 10.1038/sj.bjc.6600796, 2376369, 12671706.
43. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001, 158:1011-1019. 10.1016/S0002-9440(10)64048-5, 1850356, 11238049.
44. van Diest PJ, Vleugel MM, van der Groep P, van der Wall E. VEGF-D and HIF-1alpha in breast cancer. J Clin Pathol 2005, 58:335. author reply 336, 1770593, 15735178.
45. van Diest PJ, Vleugel MM, van der Wall E. Expression of HIF-1alpha in human tumours. J Clin Pathol 2005, 58:335-336. 1770593, 15735178.
46. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, Paik CH, Urano Y, Choyke PL, Kobayashi H. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 2007, 13:6639-6648. 10.1158/1078-0432.CCR-07-1119, 17982120.